Senores Pharmaceuticals gains on signing agreement to acquire ANDAs from Teva Pharmaceuticals USA, Inc
Senores Pharmaceuticals is currently trading at Rs. 683.85, up by 10.65 points or 1.58% from its previous closing of Rs. 673.20 on the BSE.
The scrip opened at Rs. 687.75 and has touched a high and low of Rs. 687.75 and Rs. 667.65 respectively. So far 17057 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 718.20 on 30-Jul-2025 and a 52 week low of Rs. 440.00 on 13-Jan-2025.
Last one week high and low of the scrip stood at Rs. 687.75 and Rs. 632.50 respectively. The current market cap of the company is Rs. 3154.67 crore.
The promoters holding in the company stood at 45.78%, while Institutions and Non-Institutions held 13.18% and 41.04% respectively.
Senores Pharmaceuticals through its wholly-owned subsidiary -- Senores Pharmaceuticals, Inc., USA (SPI) has signed agreement to acquire two products of USFDA approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA, Inc.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by the company. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
